Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biostar Pharmaceuticals, Inc. (BSPM)
Xianyang, SN, CN
Biostar Pharmaceuticals, Inc. develops, manufactures, and markets pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides OTC products, such as Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. In addition, the company provides prescription pharmaceutical products, including Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. It sells its products through distributors and website that serves as internet-based China Hepatitis Internet Hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.92% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-91.2% Q3'17: -100.0% (vs Q3'16)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+78.0% ★ Q3'17: +93.0% (vs Q3'16)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+115.4%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-119.1%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-7.3% Q3'17: -0.8% (vs Q3'16)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.9% Q3'17: +19.3% (vs Q3'16)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.37× Q3'17: 2.73× (vs Q3'16)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Waiping Liu | 427.0K | 16.20% | 427.0K | — | 427.0K | 10.00 | IN | Hong Kong SAR | 2018-07-02 | ↗ |
| 2 | (10) | 56.6K | 2.10% | — | 56.6K | — | 56.6K | HC, IN | United States America | 2016-10-19 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2012-04-20 | Pan Zibing | Officer | A-Award | A | Options to purchase shares of common stock | 24,000 | 0.00 | — | 64,000 | — | ↗ |
| 2012-04-07 | Pan Zibing | Officer | — | D | Options to purchase shares of Common Stock | 70,000 | 0.00 | — | 0 | — | ↗ |
| 2011-06-16 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 13,800 | 1.10 | 15.2K | 9,166,973 | — | ↗ |
| 2011-06-15 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 14,350 | 1.19 | 17.1K | 9,153,173 | — | ↗ |
| 2011-06-14 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 35,100 | 1.23 | 43.2K | 9,138,823 | — | ↗ |
| 2011-06-13 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 22,050 | 1.24 | 27.3K | 9,103,723 | — | ↗ |
| 2011-06-10 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 19,700 | 1.21 | 23.7K | 9,081,673 | — | ↗ |
| 2011-06-09 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 12,000 | 1.22 | 14.7K | 9,061,973 | — | ↗ |
| 2011-06-08 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 34,600 | 1.26 | 43.7K | 9,049,973 | — | ↗ |
| 2011-06-07 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 8,600 | 1.25 | 10.8K | 9,015,373 | — | ↗ |
| 2011-06-06 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 10,300 | 1.24 | 12.8K | 9,006,773 | — | ↗ |
| 2011-06-03 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 6,900 | 1.27 | 8.8K | 8,996,473 | — | ↗ |
| 2011-06-02 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 12,200 | 1.29 | 15.7K | 8,989,573 | — | ↗ |
| 2011-06-01 | Wang Ronghua | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 100 | 1.38 | 138.00 | 8,977,373 | — | ↗ |
| 2011-05-19 | Pan Zibing | Officer | P-Purchase | A | Common Stock | 30,000 | 1.41 | 42.3K | 30,000 | — | ↗ |
| 2009-10-22 | Wang Ronghua | Director / Officer / 10% Owner | — | D | Options to purchase Common Stock | 200,000 | 2.60 | 520.0K | 0 | — | ↗ |
| 2007-11-01 | Wang Ronghua | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 8,966,973 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ronghua Wang | Chairman, Chief Executive Officer & President | 16.3K | male |
| Zhenghong Wang | Chief Operating Officer | 6.1K | male |
| Shuang Gong | Director of Administration & Secretary of Board | — | female |
| Xiaohui Zheng | Chief Scientist | — | — |
| Xiaojuan Zhai | Chief Financial Officer | — | female |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BSPM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
